DK1289534T3 - Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser - Google Patents
Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelserInfo
- Publication number
- DK1289534T3 DK1289534T3 DK01935896T DK01935896T DK1289534T3 DK 1289534 T3 DK1289534 T3 DK 1289534T3 DK 01935896 T DK01935896 T DK 01935896T DK 01935896 T DK01935896 T DK 01935896T DK 1289534 T3 DK1289534 T3 DK 1289534T3
- Authority
- DK
- Denmark
- Prior art keywords
- apoptotic
- treatment
- inflammatory disorders
- devices
- cell mediated
- Prior art date
Links
- 230000001640 apoptogenic effect Effects 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2309518 CA2309518A1 (en) | 2000-05-25 | 2000-05-25 | Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1289534T3 true DK1289534T3 (da) | 2006-03-20 |
Family
ID=4166254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01935896T DK1289534T3 (da) | 2000-05-25 | 2001-05-25 | Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20020051771A1 (enExample) |
| EP (2) | EP1669081A1 (enExample) |
| JP (1) | JP2003534281A (enExample) |
| AT (1) | ATE311191T1 (enExample) |
| AU (1) | AU2001261986A1 (enExample) |
| CA (1) | CA2309518A1 (enExample) |
| DE (1) | DE60115432T2 (enExample) |
| DK (1) | DK1289534T3 (enExample) |
| ES (1) | ES2254424T3 (enExample) |
| TW (1) | TWI249404B (enExample) |
| WO (1) | WO2001089536A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2327631A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Inflammatory cytokine secretion inhibition |
| US7727523B2 (en) * | 2001-08-13 | 2010-06-01 | Yale University | Method for suppressing immune system response to transplanted tissue or cells |
| WO2003015850A1 (en) * | 2001-08-13 | 2003-02-27 | Edelson Richard Leslie | Method for inducing selectively suppressed immune response |
| EP1469733A4 (en) * | 2001-11-29 | 2008-07-23 | Therakos Inc | METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS |
| US8524495B2 (en) | 2007-05-16 | 2013-09-03 | Yale University | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| JP6483023B2 (ja) * | 2012-12-06 | 2019-03-13 | エンリヴェックス セラピューティクス リミテッド | 治療用アポトーシス細胞調製物、その製造方法及びその使用 |
| US11512289B2 (en) * | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| CA3014885A1 (en) * | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2023209709A1 (en) * | 2022-04-27 | 2023-11-02 | Enlivex Therapeutics Rdo Ltd | Apoptotic cell - chemotherapy combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980954A (en) * | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| CA2309424A1 (en) * | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| CA2309417A1 (en) * | 2000-05-25 | 2001-11-25 | Anthony E. Bolton | Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| EP1469733A4 (en) * | 2001-11-29 | 2008-07-23 | Therakos Inc | METHOD FOR PRE-TREATING A PATIENT WITH EXTRACORPORAL PHOTOPHERESIS AND / OR APOPTOTIC CELLS |
-
2000
- 2000-05-25 CA CA 2309518 patent/CA2309518A1/en not_active Abandoned
-
2001
- 2001-05-25 DK DK01935896T patent/DK1289534T3/da active
- 2001-05-25 DE DE2001615432 patent/DE60115432T2/de not_active Expired - Fee Related
- 2001-05-25 JP JP2001585780A patent/JP2003534281A/ja not_active Withdrawn
- 2001-05-25 AU AU2001261986A patent/AU2001261986A1/en not_active Abandoned
- 2001-05-25 ES ES01935896T patent/ES2254424T3/es not_active Expired - Lifetime
- 2001-05-25 US US09/866,488 patent/US20020051771A1/en not_active Abandoned
- 2001-05-25 WO PCT/CA2001/000758 patent/WO2001089536A2/en not_active Ceased
- 2001-05-25 AT AT01935896T patent/ATE311191T1/de not_active IP Right Cessation
- 2001-05-25 EP EP20050025962 patent/EP1669081A1/en not_active Withdrawn
- 2001-05-25 EP EP01935896A patent/EP1289534B1/en not_active Expired - Lifetime
- 2001-06-01 TW TW90113342A patent/TWI249404B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001261986A1 (en) | 2001-12-03 |
| WO2001089536A2 (en) | 2001-11-29 |
| WO2001089536A3 (en) | 2002-08-01 |
| ES2254424T3 (es) | 2006-06-16 |
| TWI249404B (en) | 2006-02-21 |
| CA2309518A1 (en) | 2001-11-25 |
| HK1055079A1 (en) | 2003-12-24 |
| EP1289534A2 (en) | 2003-03-12 |
| EP1669081A1 (en) | 2006-06-14 |
| DE60115432D1 (de) | 2006-01-05 |
| US20020051771A1 (en) | 2002-05-02 |
| EP1289534B1 (en) | 2005-11-30 |
| JP2003534281A (ja) | 2003-11-18 |
| ATE311191T1 (de) | 2005-12-15 |
| DE60115432T2 (de) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1289534T3 (da) | Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser | |
| BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
| GEP20063799B (en) | Tropane derivatives useful in therapy | |
| EA200501095A1 (ru) | Фенилацетамиды и их применение в качестве модуляторов глюкокиназы | |
| DK1071439T3 (da) | Hybenformuleringer som antiinflammatorisk naturmedicin til lindring/reduktion af symptomer associeret med inflammation og artritis | |
| DK0713701T3 (da) | 2-Brommelatonin til behandling af søvnforstyrrelser | |
| DK0607128T4 (da) | Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker | |
| DK1411932T3 (da) | Kombinationsterapi med substituerede oxazolidinoner | |
| IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
| NO20060424L (no) | 5-heteroringbaserte P38 kinaseinhibitorer | |
| BR0014912A (pt) | Tratamento de distúrbios do sono usando desloratadina | |
| DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
| DE60336664D1 (de) | Nichtnukleosidische reverse-transkriptase-hemmer | |
| ATE232396T1 (de) | Oxydiertes thymosin beta 4 | |
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| NO20013004D0 (no) | Anvendelse av biokjemiske substanser i en sammensetning for forhindringen og behandlingen av helsetilstander forårsaket avkonstriksjon av glattmuskelceller i organer i det menneskeligelegemet | |
| EA200400548A1 (ru) | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) | |
| DK1289535T3 (da) | Apoptotiske enheder til anvendelse ved behandling af neurodegenerative og andre neurologiske sygdomme | |
| AR037524A1 (es) | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion | |
| DE69111974D1 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
| WO2001089538A3 (en) | Apoptotic entities for use in treatment of endothelium dysfunction disorders | |
| NO20032006D0 (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser | |
| ATE417620T1 (de) | Antipyretikum und herstellungsverfahren dafür | |
| NZ515173A (en) | Treatment of hypersensitivity reaction disorders | |
| ATE285243T1 (de) | Medizinische salbe sowie deren herstellungsverfahren |